Objectives: Osteoarthritis (OA) is a highly prevalent condition seen across primary care services. Although evidence-based guidelines have encouraged the prescription of medications, including analgesics, for this population, there remains uncertainty as to which types of individuals actually take prescribed or over-the-counter medications. The purpose of the present study was to determine whether there is a difference in characteristics between people who take medicines for OA compared with those who do not. 95% CI: 1.03 to 1.14) were more likely to take OA medicines.
have demonstrated moderate to good effect sizes for those who follow this advice, patient experiences surrounding the effectiveness, particularly of paracetamol, have been shown to influence the extent to which pain relief is used (Lee, Cooke, Cooper, & Shield, 2017) . Furthermore, Wang, Xu, Hunter, and Ding (2015) highlighted the importance which some medications, such as strontium ranelate, may offer in respect to symptom improvement and joint structure changes, with a slowing of disease progression (Rodrigues, Freire, Bonfim, Cartágenes, & Garcia, 2018) . Accordingly, encouraging the management of OA symptoms with medicines, particularly in the early stages of the disease, could have longer-term beneficial consequences (Han, Fan, Bai, & Ding, 2017) .
Previous research has suggested that increasing age, gender, social circumstance, education and socioeconomic status may be associated with medication taking for people with musculoskeletal pain (Fisher, Ballantyne, & Hawker, 2012; Mody, Jolly, Kwasny, & Block, 2008; Pokela, Bell, Lihavainen, Sulkava, & Hartikainen, 2010) . Pain severity and mobility limitation have also been identified as important factors for those with chronic pain (Fisher et al., 2012; Mody et al., 2008; Pokela et al., 2010) . However, owing to limited sample sizes and variation in how musculoskeletal pain is categorized, there remains confusion as to who is most likely to take medication for this condition. It also remains unclear whether medication taking for OA differs from that for other chronic diseases which this population may also have, and the extent to which taking medicines for other conditions influences taking medicines for OA. As such, it is important to ascertain if those already taking medicines for these conditions are more likely to take medicines for OA as this could significantly affect both their health and well-being (Fisher et al., 2012) .
Based on these uncertainties, the purpose of the present analysis was to determine whether there is a difference in characteristics between people who are taking medicines for OA compared with those who are not. We also compared medication taking for OA to that for other long-term conditions, such as diabetes, hypertension or thrombotic diseases.
| METHODS

| Cohort
Data were gathered from the English Longitudinal Study of Ageing (ELSA), a prospective, population-based cohort study consisting of 11,391 individuals born on or before 29 February 1952 (Steptoe, Breeze, Banks, & Nazroo, 2013) .This was a nationally representative cohort which commenced in 2002 and had been followed every 2 years since then (Steptoe et al., 2013) . Ethical approval was provided by the London Multi-Centre Research Ethics Service (MREC/01/2/ 91). Anonymized unlinked data for the present study were obtained from the UK Data Service.
| Participants
Participants were eligible if they reported hip and/or knee OA with a visual analogue scale (VAS) pain score of 1 or above from a 0 to 10 pain scale. A threshold of VAS pain score of 1 was adopted to ensure that included participants presented with symptomatic arthritis.
Although it is acknowledged that this may be considered a low score, the mean and standard deviation (SD) values indicate that the cohort had substantially greater pain scores than the 1-point threshold (hip: 6.9 [1.9]; knee: 5.0 [2.9]). Included respondents were also required to report whether they were or were not taking medications for OA symptoms.
| Data collection
Data were gathered from Wave 4 of the ELSA cohort (2008) (2009) (Steptoe et al., 2013) . The HSE is an annual cross-sectional survey that was designed to monitor the health of the general population. The total sample of 11,050 from Wave 4 included 8,643 who attended a nurse visit to collect biomarkers and more detailed measures of function. Data from this analysis consisted of participants who attended the nurse clinic, with wider demographic information gathered from the face-to-face follow-up interviews.
For this analysis, all potentially eligible participants presenting data for analysis were included. This consisted of a cohort of 654 participants.
| Dependent variables
Medication taking was self-reported and categorized in a binary code of yes/no. Medication-taking was asked towards OA medication, in addition to anticoagulation, diabetes and hypertension medications which were collected as part of the routine data collection processes for the wider ELSA study.
| Covariates
Data on covariates were identified from the ELSA Wave 4 data as having a plausible relationship to explain medication taking for this population from a biological, psychological or social standpoint. Accordingly, the data included in the analysis were: age, gender, weight, ethnic classification (white/nonwhite), whether participants were in paid work or not and the National Statistics Socio-Economic Classification (NS-SEC) scheme category (Shankar, McMunn, Banks, & Steptoe, 2011) . We also extracted data on self-reported general health and whether participants had access to a car. It was therefore hypothesized that these data may provide some explanation for medication taking from perspectives such as disease-specific, impairment or activity related, from social or economic factors in addition to representing health psychological factors across this national cohort (Steptoe et al., 2013) .
The pain measurements extracted included: VAS hip and knee pain score, duration of hip and/or knee pain and location of OA, categorized as isolated hip, isolated knee, or hip and knee. activity (Demakakos, Hamer, Stamatakis, & Steptoe, 2012; Garfield, Llewellyn, & Kumari, 2016) . This method has been used to determine the level of physical activity participation undertaken by older people (Demakakos et al., 2012; Garfield et al., 2016) , and has demonstrated excellent convergent validity within this population (Hamer et al., 2009 ).
Cognitive function was determined using the ELSA index of executive function. This is based on two brief tests of executive function:
verbal fluency and letter cancellation. Verbal fluency evaluates self-initiated activity, organization and abstraction/mental flexibility. For this task, participants were given 1 min to name as many animals as possible. The number of animals named was recorded). Letter cancelation assesses attention, visual searching and mental speed. Participants were provided with a page of random letters arranged in rows and columns and asked to cross out as many target letters ('P' and 'W') within 1 min (Steptoe et al., 2013) . These tests have demonstrated reliability and validity in assessing executive function (Henry & Crawford, 2004; Lezak, 1995; Tombaugh, Kozak, & Rees, 1999; Uttl & Pilkenton-Taylor, 2001 ).
Objectively assessed physical performance measurements were collected during the nurse assessment visit. These included: gait speed using an 8 feet (2.4 m) walking test performed at normal walking pace; dominant handgrip strength; and time taken for five and 10 chair raises.
Functional impairment in activities of daily living (ADL) and instrumental ADLs was assessed by participants' response to whether they found difficulty in performing 18 personal and extended ADLs (Steptoe et al., 2013) . These are itemized in Table 1 . (Table 2) . There was no significant relationship between taking medication for OA compared with anticoagulants (p = 0.78), medicines for diabetes (p = 0.79) or medicines for hypertension (p = 0.65), as presented in Table 3 .
| Data analysis
| Characteristics of cohort
| CONCLUSIONS
The findings of the present study indicate that three variables were associated with whether individuals took medication for their OA symptoms. Individuals who had access to a car, had a longer duration of hip pain and could complete 10 chair raises from a chair at greater speed were more likely to take medications for their OA. There was no relationship between taking medications for OA compared with anticoagulants or medicines for diabetes or hypertension. Given that taking medicines (such as strontium ranelate (Rodrigues et al., 2018) ) can slow OA disease progression and improve both pain and structural changes (Han et al., 2017; Wang et al., 2015) , encouraging medicine taking for those at risk of not taking medicines, is clinically warranted. This is further encouraged by the present data, which indicated greater functional performance, as measured by timed chair raises, for individuals who took medications compared with those who did not. This suggests that individuals who take medications may be more physically capable than those who do not.
The duration of hip pain was reported as a significant predictor of medication taking. This may relate to people having had the disease for a longer period, and therefore more opportunity to take medicines (Rillo et al., 2016) . It was not possible to negate the problem of reverse causation using concurrent measures of pain and medication taking.
Nonetheless, duration of hip pain may also relate to long-term health beliefs, advocating the advantages of medication control for hip symptoms. Although reported as potential candidate variables, the variables of hip and knee pain scores were not reported as significant predictors of medication taking. This contrasts with previous findings which suggested that pain severity and associated reduced mobility are significant predictors of medication taking in other musculoskeletal cohorts (Fisher et al., 2012; Mody et al., 2008; Pokela et al., 2010) . The mean VAS scores for the cohorts were between 5 and 7. Therefore, it remains unclear whether medication taking differs between participants with higher and lower scores, given that the cohort presented with minimal variance. Further exploration, with cohorts who present with different pain severities, might therefore be prudent.
There was a difference in medication taking between people who reported hip, knee or multi-site OA. A greater proportion of participants with hip and knee OA presented in the medication-taking group (47%), although it is unclear why this should have been the case. One hypothesis is that there is a difference in health beliefs towards managing more global (whole-body) symptoms with medications in those with multi-site OA compared with individuals with single-joint pathology. There remains limited evidence for different symptom management approaches for those with single-joint compared with multijoint pathology (Comer et al., 2018) . Further exploration on why individuals with multi-joint pain are more likely to take medications would be useful. Examination of previous consultations with healthcare professionals, symptom levels and attitudes towards OA would be beneficial areas for investigating, to help our understanding of why this difference occurs.
The findings of the present study indicate no association between taking medication for OA and for other chronic diseases. This conflicts with previous literature which has suggested a disconnect in practices, whereby people are more likely to take medications for cardiovascular disease and diabetes management compared with OA (Sale, Gignac, & Hawker, 2006) . These studies have suggested that patients are more likely to take medications to control blood pressure or blood sugar, or reduce the risk of thrombotic events than to take medication for OA. The difference may be attributed either to a difference in outcome for this population compared with those who are older, or to coming from countries other than France (Alami et al., 2011) , Australia (Laba, Brien, Fransen, & Jan, 2013; Milder, Lipworth, Williams, Ritchie, & Day, 2011) and Canada (Sale et al., 2006) , where the current evidence arises from. The results might also be attributable to the sample size, with the subgroup analysis consisting of between 90 and 259 participants (Table 3) , so the nonstatistically significant finding may be the result of type II statistical error.
Previous research has suggested that increasing age, gender, social circumstance, education and socioeconomic status, in addition to pain severity and mobility impairment, may be associated with medication use (Fisher et al., 2012; Mody et al., 2008; Pokela et al., 2010) .
This cohort of community-dwelling individuals from England suggests that whilst there was no significant relationship on logistical regression analysis on medication adherence for age, gender or education, the variable as to whether individuals have access to a car may be viewed as a surrogate for social circumstance or socioeconomic status. It remains unclear whether this factor should be interpreted in respect to the economics of not being able to afford access to transport, which has been previously reported as a factor (Macintyre et al., 1998) , or as a marker for social isolation and loss of social capital (Drennan et al., 2008) . Both factors have been suggested to have a major impact on quality of life (Woodcock & Aldred, 2008) and hence should be considered as important factors for people with OA.
The present study highlighted subgroups of the OA population who are at risk of not taking medications (i.e. people without access to a car, those with a shorter duration of disease and who take longer to complete 10 chair raises). Previous literature has identified strategies which health professionals may adopt to address such behaviours.
These include educating patients about conditions and medicines, so OA, osteoarthritis supported through education on the different types of drugs available and how to use them to relieve symptoms and improve their health and well-being.
Although the study had considerable strengths, most notably its sample size for the primary analysis and national representation for people presenting with OA, it presented with two key limitations.
Firstly, the findings on medication taking were self-reported. Accordingly, both recall and social desirability bias may have affected the findings, either to supress or inflate estimated medication-taking practice. This might have been negated through using techniques for validating medication taking, such as pill counts or reported prescription counts. However, as the data from the ELSA cohort was anonymized, such validation approaches could not be used. Secondly, it was not possible to ascertain whether there was a difference in medication taking between simple medications such as paracetamol or NSAIDs, and opioid-based medications. Assessing the differentiation of medication taking by medication type would provide further detail to the analysis and may give greater insights into the medication-taking behaviours of people with OA.
To conclude, the findings of the present study indicated that access to a car, duration of hip pain and time to complete 10 chair raises are significant predictors of whether individuals with hip and/ or knee OA take medications. Further study, to consider the strategies that should be used to support better those individuals at greatest risk, would be advantageous, given the current evidence-based recommendation that individuals with OA should take medications to improve their health and well-being significantly and reduce the burden on primary and secondary care services of not taking medicines for OA symptoms.
